Cedars Sinai Research Updates in Lymphoma 2025

• Target Audience: hematologists, oncologists, pathologists
• Sample video: contact me for sample video
• Information:

Target Audience

Specialties – Hematology, Imaging, Internal Medicine, Oncology, Pathology & Laboratory Medicine, Radiation Oncology, Radiology, Surgery

Professions – Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Other (non-physician), Physician, Physician Assistant, Researcher (non-physician), Researcher (physician)

Overview

This conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, “How I Treat” sessions will address questions of sequencing therapies and patients selection. The scientific sessions will present high impact basic science with high translational relevance, such as new biomarkers, therapeutic targets and novel cellular therapies.

Objectives

Recognize the utility of molecular testing in the classification and treatment of lymphoma

Identify current evidence based treatments for Hodgkin lymphoma, diffuse large B cell lymphoma, and peripheral T cell lymphoma

Describe new treatments under development including bi specific antibodies and CART therapies

Collaborate as an interprofessional healthcare team to evaluate the role of molecular testing in lymphoma classification, apply evidence based treatments for various lymphoma subtypes, and discuss emerging therapies such as bispecific antibodies and CAR T cell therapies to optimize patient care through shared knowledge and coordinated decision making

• Topics:

Saturday, October 18, 2025

Session 1: Hot Topics in Clinical Lymphoma – Part I

Session Chair: TBD

Frontline Therapy for Advanced Hodgkin Lymphoma: ECHELON-1, SWOG S1826, and GHSG HD21 (BrECADD) Updates

Joe Schroers-Martin, MD

Matthew G. Mei, MD

Dual Targeting CART for Lymphoma

Akil Merchant, MD

Break and Exhibits

Session 2: Hot Topics in Clinical Lymphoma – Part II

Session Chair: Justin Darrah

T-Cell Lymphoma

Wen-Kai Weng, MD, PhD

Role of Radiation Therapy in Lymphoma

Parag Sanghvi, MD

Lightning Round

Lightning Round: Open Clinical Trials for Lymphoma in LA area (90 sec per trial)

Lunch and Networking

Lunch and Exhibits

Session 3: Keynote & Basic Science Insights

Session Chair: Akil Merchant, MD

KEYNOTE ADDRESS: Spatial Profiling in Lymphoma Transformers: More than Meets the Eye

Mina Xu, MD

Microenvironment in Non-Hodgkin Lymphoma

Anthony R Colombo, PhD

Hidden Opponents: The DLBCL Microenvironment

David Russler-Germain, MD, PhD

Metabolic Profiling and Modulation of the Lymphoma Microenvironment

Akil Merchant, MD

Break and Exhibits

Session 4: Next Generation Diagnostics and Biomarkers

Session Chair: Joseph C. Lownik, MD

Lymphoma Biomarker Development: Lessons Learned from Gene Expression Profiling

Lisa M Rimsza, MD

Developing an Automated Multiplex IF for Diagnostic/Biomarker Use in Lymphoma

Joseph C. Lownik, MD

Role of ct DNA in Lymphoma

Brian Sworder, MD, PhD

Assessments and Therapies for Older Patients with Aggressive Lymphomas

Elizabeth Brem, MD

Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in DLBCL

Sean R Corcoran , MD, PhD

Adjourn

Networking Reception

Networking Reception

Sunday, October 19, 2025

Session 1: CAR-T Cell Therapy: Managing Complex Toxicities

Session Chair: Hitomi Hosoya, MD, PhD

Mechanisms of Neurotoxicity with IEC and Bispecific Therapies

Juliane Gust, MD, PhD

IEC-HS: Diagnosis (ASTCT Criteria), Pathophysiology, and Management

Hrishikesh Srinagesh, MD

Prophylactic Strategies for CAR-T Toxicities: Role of Early Steroids, Anakinra, and Other Novel Approaches

Caspian Oliai, MD

Secondary and T-cell Malignancies after CAR T-cell Therapy

Hitomi Hosoya, MD, PhD

Break and Exhibits

Session 2: Clinical Debate–What is the Optimal Bridging Strategy for CAR-T Therapy

Session Chair: Justin Darrah, MD

Intro: Why bridging?

Justin Darrah, MD

Role of Bispecifics as Bridging

Justin Darrah, MD

Radiation as Bridging

Parag Sanghvi, MD

Optimal Chemotherapy for Bridging

David R. Oveisi, MD

Debate and Discussion

BREAK/EXHIBITS

Session 3: Next Generation Cellular Therapies for Lymphoma and Beyond (Non Accredited)

Session Chair: Yvonne Chen, PhD

Novel CART for Solid Tumors

Yvonne Chen, PhD

Innovations in TIL Therapy

Giri Ramsingh , MD

Macrophage Based Therapies

Ann Liu, Other

Engineered Protein Circuits for Cancer Therapy

Michael B. Elowitz, PhD

Closing and Lunch